Mouse Tumor Biology Database (MTB)
MTB Home   Help
Search for Help
 
in these sections
Search Forms
Tumor
Strain
Genetics
Pathology Images
Reference
Advanced
Search MTB Using Human Genes
Gene Expression Data Sets

Additional Resources
new PDX Like Me
PDX Finder
PDX Model Search
Faceted Tumor Search
Dynamic Tumor Frequency Grid
Other Cancer Websites
Immunohistochemistry
Lymphoma Pathology

Mouse Genome Informatics
The Jackson Laboratory
Citing These Resources
Warranty Disclaimer
& Copyright Notice

Send Questions and
Comments to User Support.

Last Database Update
2019-12-08
MTB 3.0
 
HelpHelp and Documentation Reference Detail  
Reference
Title: Tg.AC genetically altered mouse: assay working group overview of available data.
Authors: Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Journal: Toxicol Pathol
Volume: 29 Suppl
Issue:
Year: 2001
Pages: 60-80
Abstract: In a Government/Industry/Academic partnership to evaluate alternative approaches to carcinogenicity testing, 21 pharmaceutical agents representing a variety of chemical and pharmacological classes and possessing known human and or rodent carcinogenic potential were selected for study in several rodent models. The studies from this partnership project, coordinated by the International Life Sciences Institute, provide additional data to better understand the models' limitations and sensitivity in identifying carcinogens. The results of these alternative model studies were reviewed by members of Assay Working Groups (AWG) composed of scientists from government and industry with expertise in toxicology, genetics, statistics, and pathology. The Tg.AC genetically manipulated mouse was one of the models selected for this project based on previous studies indicating that Tg.AC mice seem to respond to topical application of either mutagenic or nonmutagenic carcinogens with papilloma formation at the site of application. This communication describes the results and AWG interpretations of studies conducted on 14 chemicals administered by the topical and oral (gavage and/or diet) routes to Tg.AC genetically manipulated mice. Cyclosporin A, an immunosuppresant human carcinogen, ethinyl estradiol and diethylstilbestrol (human hormone carcinogens) and clofibrate, an hepatocarcinogenic peroxisome proliferator in rodents, were considered clearly positive in the topical studies. In the oral studies, ethinyl estradiol and diethylstilbestrol were negative, cyclosporin was considered equivocal, and results were not available for the clofibrate study. Of the 3 genotoxic human carcinogens (phenacetin, melphalan, and cyclophosphamide), phenacetin was negative by both the topical and oral routes. Melphalan and cyclophosphamide are, respectively, direct and indirect DNA alkylating agents and topical administration of both caused equivocal responses. With the exception of clofibrate, Tg.AC mice did not exhibit tumor responses to the rodent carcinogens that were putative human noncarcinogens, (di(2-ethylhexyl) phthalate, methapyraline HCl, phenobarbital Na, reserpine, sulfamethoxazole or WY-14643, or the nongenotoxic, noncarcinogen, sulfisoxazole) regardless of route of administration. Based on the observed responses in these studies, it was concluded by the AWG that the Tg.AC model was not overly sensitive and possesses utility as an adjunct to the battery of toxicity studies used to establish human carcinogenic risk.
Additional
Information
in MTB
Tumor Records (415)
Strains (3)
Other
Accession
IDs
J:73017  Mouse Genome Informatics
11695563  National Library of Medicine/PubMed